Technological Advances in Genetics Testing: Implications for the Future : Hearing Before the Subcommittee on Technology of the Committee on Science, U.S. House of Representatives, One Hundred Fourth Congress, Second Session, September 17, 1996, Volume 4U.S. Government Printing Office, 1996 - 191 pages Distributed to some depository libraries in microfiche. |
Other editions - View all
Common terms and phrases
American Pathologists analytical appropriate bill Bioethics BRCA1 breast cancer cell chromosomes CLIA clinical laboratory clinical validity College of American Collins Committee confidentiality CONG CONGRE CONGRESS THE LIBRARY Cossman coverage cystic fibrosis Cytogenetics diagnostic Drug Testing ensure ethical federal Force on Genetic gene genetic discrimination genetic disease genetic information genetic research genetic testing genetic testing services GRES GRESS GRODY guidelines HCFA health insurance Human Genome Project Huntington's disease identified implications individual informed consent inspection issues laboratories performing Laboratory Accreditation Program legislation LIBRARY OF CONGRESS Madam Chairwoman medical information medical record MORELLA mutations netic ovarian ovarian cancer oversight Pathology patient Pendergast physicians predictive professional proficiency testing prohibited protection quality assurance questions RARY regulations requirements RESS risk scientific September 17 society specific specimens standards Subcommittee on Technology Task Force Thank therapy tion
Popular passages
Page 111 - It is not enough that you should understand about applied science in order that your work may increase man's blessings. Concern for man himself and his fate must always form the chief interest of all technical endeavors...
Page 33 - Novitch follows:] DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville MD 20857...
Page 111 - ... in order that the creations of our mind shall be a blessing and not a curse to mankind. Never forget this in the midst of your diagrams and equations.
Page 140 - Its 75,000 members include board certified pathologists, other physicians, clinical scientists, and certified technologists and technicians. These professionals recognize the Society as the principal source of continuing education in pathology and as the leading organization for the certification of laboratory personnel.
Page 80 - Project (ELSI) for both state and federal policy makers to protect against genetic discrimination: 1. Insurance providers should be prohibited from using genetic information, or an individual's request for genetic services, to deny or limit any coverage or establish eligibility, continuation, enrollment or contribution requirements. 2. Insurance providers should be prohibited from establishing differential rates or premium payments based on genetic information, or an individual's request for genetic...
Page 80 - Cancer (NAPBC) and the Working Group on Ethical, Legal, and Social Implications of the Human Genome Project (ELSI...
Page 79 - ... example, passed legislation prohibiting health insurers from refusing to issue insurance or charging higher premiums based on sickle cell trait or hemoglobin C trait. By 1991 a new generation of state legislation began to evolve with the passage of a Wisconsin law prohibiting health insurers from: requiring or requesting an individual or a member of the individual's family to obtain a genetic test; requiring or requesting directly or indirectly into the results of a genetic test; conditioning...
Page 4 - HON. NANCY L. JOHNSON, A REPRESENTATIVE IN CONGRESS FROM THE STATE OF CONNECTICUT Mrs. JOHNSON. Thank you very much, Mr. Chairman, and thanks to all of your colleagues on your Subcommittee on Select Revenue Measures for being here this afternoon.
Page 15 - States, we have completed the first year of operation of the National Center for Human Genome Research at the National Institutes of Health (NIH), now the largest single funding source for genome research in the world.
Page 81 - ... acceptance of the whole group or to the premiums set for the group. The act would not prohibit group health plans or issuers of plans (ie, insurers) from requiring or requesting genetic testing, does not require them to obtain authorization before disclosing genetic information, and does not prevent them from excluding all coverage for a particular condition or imposing lifetime caps on all benefits or on specific benefits. In addition, this act does not address the issues of the use of genetic...